Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma

Sorafenib, an oral VEGFR-2, Raf, PDGFR, c-KIT and Flt-3 inhibitor, is active against renal cell and hepatocellular carcinomas, and has recently demonstrated promising activity for lung and breast cancers. In addition, various protracted temozolomide dosing schedules have been evaluated as a strategy...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Reardon, David A., Vredenburgh, James J., Desjardins, Annick, Peters, Katherine, Gururangan, Sridharan, Sampson, John H., Marcello, Jennifer, Herndon, James E., McLendon, Roger E., Janney, Dorothea, Friedman, Allan H., Bigner, Darell D., Friedman, Henry S.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2010
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3102498/
https://ncbi.nlm.nih.gov/pubmed/20443129
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-010-0217-6
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge